← SynDRA
NABUMETONE
SynDRA canonical compound SYN0003502 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PTGS2 |
|---|
| Mechanism of action | Cyclooxygenase inhibitor |
|---|
| Indication | osteoarthritis | rheumatoid arthritis |
|---|
| Disease area | rheumatology |
|---|
All known targets
- PTGS2
- PTGS1
- AKR1C3
- CYP1A2
- CYP2B6
- CYP2C19
- CYP2E1
- MAOA
- SLC6A2
Mechanisms of action (all sources)
- Cyclooxygenase inhibitor
- PTGS2 INHIBITOR
Drug classes
- Cyclooxygenase Inhibitors
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Cyclooxygenase 2 Inhibitors
- Enzyme Inhibitors
- Peripheral Nervous System Agents
- Sensory System Agents
- Nonsteroidal Anti-inflammatory Drug
ATC classes
- M01A · ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Cross-references
Synonyms
- nabucox
- nabumeton
- nabuton
- Nabumetona
- BRL-14777
- NSC-758623
- Relafen
- Relifex
- NNB-001
- NNB-004
- NNB-005
- Nabumetone (oral)
- Nabumetone (oral), Nobex
- 6-MNA (oral), Nobex
- 4-(6-Methoxy-2-naphthyl)-2-butanone
- NSC 758623
- nabumetone (ep monograph)
- nabumetone (usp impurity)
- BRL 14777
- LW0TIW155Z
- 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-
- nabumetone (usp-rs)
- nabumetone (usp monograph)
- 4-(6-methoxynaphthalen-2-yl)butan-2-one
- Nabumetonum
- 4-(6-Methoxy-2-naphthalenyl)-2-butanone
- CHEBI:7443
- DTXCID2025472
- Nabumetone [USAN:USP:INN:BAN:JAN]
- ApoNabumetone
- Rhoxal nabumetone
- Nabumetone (USAN:USP:INN:BAN:JAN)
- Nabumetone 500 mg
- Nabumetone 750 mg
- RELAFEN DS
- Nabumetone 1000 mg
- RefChem:55684
- M01AX01
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Albuminuria
- Dizziness
- Nightmare
- Pruritus
- Thrombocytopenia
- Tinnitus
- Vasculitis
- Bilirubinuria
- Acne
- Anaphylactoid reaction
Look up NABUMETONE in the interactive SynDRA portal →